BMS 986148

Drug Profile

BMS 986148

Alternative Names: BMS-986148; Mesothelin-ADC - BMS

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action Megakaryocyte potentiating factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Japan (IV) (NCT02884726)
  • 20 Sep 2016 Bristol-Myers Squibb plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in Japan (NCT02884726)
  • 01 Jun 2015 Phase-I/II clinical trials in Solid tumours (Late-stage disease) in Australia (IV) (NCT02341625)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top